Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Medulloblastoma 1Ependymoma 1

Interventions

Specimen Handling 67Magnetic Resonance Spectroscopy 52Cyclophosphamide 44Vincristine 37Radiotherapy 30Radiation 30Cisplatin 30Carboplatin 29Dexamethasone 27Etoposide 26Doxorubicin 25Biopsy 25daratumumab 17Radiotherapy, Intensity-Modulated 17Prednisone 17Paclitaxel 16Irinotecan 16Cytarabine 16durvalumab 15Platinum 15Gemcitabine 15Observation 14Methotrexate 14Leucovorin 14Docetaxel 141,2-diaminocyclohexaneplatinum II citrate 14Lenalidomide 13X-Rays 12Watchful Waiting 12Rituximab 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Antipyretics × 1 year × Clear all
NCT04743661 2026-02-05

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

Pediatric Brain Tumor Consortium

Phase 2 Active not recruiting
62 enrolled
CNS

Ependymoma, Medulloblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡